Press Releases Genprex, Inc.

Equities

GNPX

US3724462037

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-03 pm EDT			5-day change	1st Jan Change
2.44 ^USD	+3.39%		+10.41%	-73.48%

Apr. 03	Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer	CI
Apr. 02	Genprex, Inc. Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting	Apr. 10	AQ
Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex Delivery System	Apr. 03	AQ
Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules	Mar. 20	AQ
Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers	Mar. 13	AQ
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting	Mar. 07	AQ
Genprex Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators	Feb. 08	AQ
Genprex to Present at Upcoming BIO CEO and Investor Conference	Feb. 07	AQ
Genprex to Present at BIO-Europe 2023 Conference	Nov. 02	AQ
AACR-NCI-EORTC International Conference 2023 – Completion of Acclaim-1 Dose Escalation: Recommended Phase 2 Dose of Quaratusugene Ozeplasmid Gene Therapy and Osimertinib	23-10-12	PU
Genprex Inc. (NASDAQ: GNPX) Receives Orphan Drug Designation for Immunogene Therapy for Treatment of SCLC	23-09-21	GL
Genprex Granted FDA Orphan Drug Designation for REQORSA Immunogene Therapy for the Treatment of Small Cell Lung Cancer	23-08-11	AQ
CapitalGainsReport Penny Stock Bounce List: EPAZ, ARDS, FRTX, GNPX	23-07-24	AQ
Genprex Announces $7.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules	23-07-20	AQ
Genprex Signs Exclusive License to Additional Diabetes Technology with the University of Pittsburgh	23-07-19	AQ
IBN Announces Latest Episode of The Bell2Bell Podcast featuring CEO Rodney Varner & CFO Ryan Confer of Genprex, Inc.	23-07-06	AQ
BigTime Penny Stocks: Stocks to Watch: GNPX, MRES, DVLP, EMGE	23-06-29	AQ
BigTime Penny Stocks: Potential Breakout Stocks - Watchlist (GNPX, CLNV, CNBX, WOEN)	23-06-02	AQ
BigTime Penny Stocks: Rapid Growth in Gene Therapy Market (GNPX, LEAS;RWOD, VYGR, AVRO)	23-06-01	AQ
Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Expansion Portion of Acclaim-1 Clinical Trial of REQORSA in Combination with Tagrisso in Advanced Non-Small Cell Lung Cancer	23-05-31	AQ
Genprex : Updates on Acclaim-1 Clinical Trial - Form 8-K	23-05-26	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Genprex, Inc.

Equities

GNPX

US3724462037

Press Releases

Filters